Improving T cell therapy for blood cancers
Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL
This study is testing a new way to improve T cell therapy for people with advanced blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia, by making T cells better at finding and fighting tumors, which could lead to better results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11060889 on NIH RePORTER |
What this research studies
This research focuses on enhancing adoptive T cell therapy, a treatment for advanced blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The approach involves genetically modifying T cells to better recognize and attack tumors while maintaining their effectiveness in the challenging tumor environment. By developing a new method to reprogram these T cells, the research aims to improve their survival and function, potentially leading to better treatment outcomes for patients. Participants may receive a novel therapy that combines beneficial traits from different T cell types to enhance anti-tumor responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-Hodgkin lymphoma or chronic lymphocytic leukemia who have not responded well to standard treatments.
Not a fit: Patients with early-stage blood cancers or those who are not eligible for T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced blood cancers, improving their chances of recovery.
How similar studies have performed: Previous research has shown promising results with similar approaches in enhancing T cell therapies, indicating potential for success in this novel method.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Hess, Brian — Medical University of South Carolina
- Study coordinator: Hess, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.